X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (28) 28
humans (26) 26
index medicus (23) 23
chemotherapy (22) 22
cancer (18) 18
care and treatment (16) 16
cetuximab (13) 13
colorectal cancer (13) 13
head and neck cancer (11) 11
antineoplastic agents - therapeutic use (9) 9
risk factors (9) 9
squamous-cell carcinoma (9) 9
aged (8) 8
cancer patients (8) 8
female (8) 8
male (8) 8
phase-iii trial (8) 8
colorectal neoplasms - drug therapy (7) 7
hematology, oncology and palliative medicine (7) 7
quality-of-life (7) 7
radiotherapy (7) 7
treatment outcome (7) 7
antineoplastic agents - adverse effects (6) 6
colorectal neoplasms - pathology (6) 6
complications and side effects (6) 6
drug therapy (6) 6
head and neck neoplasms - therapy (6) 6
metastasis (6) 6
middle aged (6) 6
prognosis (6) 6
receiving cetuximab (6) 6
research (6) 6
1st-line treatment (5) 5
antibodies, monoclonal - adverse effects (5) 5
chemoradiotherapy (5) 5
growth-factor receptor (5) 5
head and neck neoplasms - drug therapy (5) 5
metastatic colorectal-cancer (5) 5
panitumumab (5) 5
patients (5) 5
patients receiving radiotherapy (5) 5
pharmacology & pharmacy (5) 5
receiving chemotherapy (5) 5
receiving radiotherapy (5) 5
skin toxicity (5) 5
adult (4) 4
animals (4) 4
antibodies, monoclonal - therapeutic use (4) 4
antineoplastic agents (4) 4
carcinoma, squamous cell - therapy (4) 4
cell lung-cancer (4) 4
cetuximab - therapeutic use (4) 4
comorbidity (4) 4
double-blind (4) 4
epidermal growth factor (4) 4
fluorouracil (4) 4
head and neck neoplasms - pathology (4) 4
head and neck neoplasms - radiotherapy (4) 4
health aspects (4) 4
locally advanced head (4) 4
management (4) 4
monoclonal antibodies (4) 4
mucositis (4) 4
mutation (4) 4
neoplasms - drug therapy (4) 4
neoplasms. tumors. oncology. including cancer and carcinogens (4) 4
oxaliplatin (4) 4
patient outcomes (4) 4
placebo-controlled trial (4) 4
plus irinotecan (4) 4
receptor, epidermal growth factor - antagonists & inhibitors (4) 4
retrospective studies (4) 4
skin (4) 4
squamous cell carcinoma (4) 4
therapy (4) 4
tumors (4) 4
usage (4) 4
aged, 80 and over (3) 3
analysis (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antibodies, monoclonal, humanized (3) 3
antimitotic agents (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
breast-cancer (3) 3
carcinoma, squamous cell - pathology (3) 3
cetuximab plus irinotecan (3) 3
clinical trials (3) 3
clinical-practice guidelines (3) 3
colorectal neoplasms - genetics (3) 3
colorectal neoplasms - metabolism (3) 3
dentistry, oral surgery & medicine (3) 3
head (3) 3
head and neck neoplasms - complications (3) 3
induced oral mucositis (3) 3
kras (3) 3
medicine & public health (3) 3
metastatic colorectal cancer (3) 3
multivariate analysis (3) 3
neck (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2016, Volume 95, Issue 5, pp. 1346 - 1354
Purpose To evaluate the severity of cetuximab-induced skin rash and its correlation with clinical outcome and late skin toxicity in patients with head and neck... 
Radiology | Hematology, Oncology and Palliative Medicine | LUNG-CANCER | SINGLE-AGENT | ONCOLOGY | MULTICENTER PHASE-II | ACUTE ORGAN TOXICITY | SQUAMOUS-CELL CARCINOMA | RECEIVING CETUXIMAB | POSITIVE PROGNOSTIC-FACTOR | COMBINATION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | METASTATIC COLORECTAL-CANCER | CHEMOTHERAPY | Prognosis | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Statistics as Topic | Cetuximab - therapeutic use | Chemoradiotherapy | Incidence | Drug Eruptions - mortality | Squamous Cell Carcinoma of Head and Neck | Carcinoma, Squamous Cell - mortality | Sensitivity and Specificity | Adult | Female | Radiodermatitis - pathology | Radiotherapy Dosage | Severity of Illness Index | Reproducibility of Results | Comorbidity | Risk Factors | Head and Neck Neoplasms - drug therapy | Head and Neck Neoplasms - therapy | Carcinoma, Squamous Cell - therapy | Survival Rate | Treatment Outcome | Head and Neck Neoplasms - pathology | Disease-Free Survival | Aged | Head and Neck Neoplasms - mortality | Causality | Radiodermatitis - mortality | Antimitotic agents | Medical colleges | Care and treatment | Cancer patients | Squamous cell carcinoma | Patient outcomes | Rash (Dermatology) | Skin | Information management | Research institutes | Antineoplastic agents | Radiotherapy | Metastasis | Index Medicus | HEAD | PATIENTS | NEOPLASMS | DERMATITIS | RADIOLOGY AND NUCLEAR MEDICINE | CORRELATIONS | NECK | RADIOTHERAPY | SKIN | GY RANGE 10-100
Journal Article
International Journal of Cancer, ISSN 0020-7136, 01/2013, Volume 132, Issue 1, pp. 236 - 245
Skin toxicity is a frequent adverse event of epidermal growth factor receptor (EGFR) targeting agents. Occurrence of cetuximab‐induced skin toxicity (Cet‐ST)... 
capecitabine | cetuximab | acneiform rash | first‐line | colorectal cancer | skin toxicity | first-line | 1ST-LINE TREATMENT | PLUS IRINOTECAN | OXALIPLATIN | BRAF | FLUOROURACIL | CHEMOTHERAPY | PHASE-III TRIAL | ONCOLOGY | MUTATION | RECEIVING CETUXIMAB | KRAS | Prognosis | Capecitabine | Skin - metabolism | Colorectal Neoplasms - genetics | Humans | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antibodies, Monoclonal, Humanized | Organoplatinum Compounds - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Female | Retrospective Studies | Cetuximab | Colorectal Neoplasms - metabolism | Camptothecin - analogs & derivatives | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Treatment Outcome | Signal Transduction - genetics | Mutation - genetics | Polymorphism, Genetic - drug effects | Mutation - drug effects | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Polymorphism, Genetic - genetics | Aged | Deoxycytidine - analogs & derivatives | Skin - drug effects | Cohort Studies | Care and treatment | Epidermal growth factor | Codon | Analysis | Colorectal cancer | Clinical trials | Skin | Metastasis | Medical informatics | Signal transduction | Chemotherapy | Toxicity | Index Medicus | Age
Journal Article
BMC Cancer, ISSN 1471-2407, 01/2016, Volume 16, Issue 1, p. 42
Journal Article
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 06/2017, Volume 117, Issue 1, pp. 15 - 24
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2016, Volume 96, Issue 5, pp. 959 - 966
Purpose We assessed the presence of salivary cytokines, their modulation during chemoradiation therapy (CTRT), and their association with oral mucositis... 
Radiology | Hematology, Oncology and Palliative Medicine | PRO-INFLAMMATORY CYTOKINES | RECEIVING RADIOTHERAPY | PROTEIN | ONCOLOGY | PATHOBIOLOGY | DRUGS | SQUAMOUS-CELL CARCINOMA | CHEMORADIOTHERAPY | INTERLEUKIN-6 | EXPRESSION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | SEVERITY | Oropharyngeal Neoplasms - therapy | Interleukin-6 - analysis | Chemoradiotherapy - adverse effects | Prospective Studies | Area Under Curve | Cytokines - analysis | Humans | Saliva - chemistry | Cisplatin - administration & dosage | Laryngeal Neoplasms - therapy | Fluorouracil - administration & dosage | Time Factors | Dose Fractionation | Severity of Illness Index | Interleukin-1beta - analysis | Nasopharyngeal Neoplasms - therapy | Radiotherapy, Intensity-Modulated - methods | Head and Neck Neoplasms - therapy | Carboplatin - administration & dosage | Carcinoma, Squamous Cell - therapy | Stomatitis - etiology | Mouth Neoplasms - therapy | Stomatitis - metabolism | Tumor Necrosis Factor-alpha - analysis | Hypopharyngeal Neoplasms - therapy | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma - therapy | Cetuximab - administration & dosage | Stomatitis | Care and treatment | Cancer patients | Chemotherapy | Cytokines | Immunotherapy | Radiation | Head and neck cancer | Radiotherapy | Epidemiology | Cancer | Index Medicus | HEAD | PATIENTS | LYMPHOKINES | NEOPLASMS | RADIATION HAZARDS | RADIOLOGY AND NUCLEAR MEDICINE | NECK | RADIOTHERAPY | CHEMOTHERAPY
Journal Article